HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Saved in:
| Title: | HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. |
|---|---|
| Authors: | Nelde A; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Kowalewski DJ; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany., Backert L; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany., Schuster H; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany., Werner JO; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Klein R; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Kohlbacher O; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.; Quantitative Biology Center, University of Tübingen, Tübingen, Germany.; Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany., Kanz L; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Salih HR; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.; Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Rammensee HG; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Stevanović S; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Walz JS; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany. |
| Source: | Oncoimmunology [Oncoimmunology] 2018 Feb 14; Vol. 7 (4), pp. e1316438. Date of Electronic Publication: 2018 Feb 14 (Print Publication: 2018). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 29632711 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Nelde+A%22">Nelde A</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kowalewski+DJ%22">Kowalewski DJ</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Backert+L%22">Backert L</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Schuster+H%22">Schuster H</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Werner+JO%22">Werner JO</searchLink>; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Klein+R%22">Klein R</searchLink>; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kohlbacher+O%22">Kohlbacher O</searchLink>; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.; Quantitative Biology Center, University of Tübingen, Tübingen, Germany.; Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kanz+L%22">Kanz L</searchLink>; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Salih+HR%22">Salih HR</searchLink>; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.; Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Rammensee+HG%22">Rammensee HG</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Stevanović+S%22">Stevanović S</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Walz+JS%22">Walz JS</searchLink>; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2018 Feb 14; Vol. 7 (4), pp. e1316438. <i>Date of Electronic Publication: </i>2018 Feb 14 (<i>Print Publication: </i>2018). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2162-4011 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29632711 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/2162402X.2017.1316438 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e1316438 Titles: – TitleFull: HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Nelde A – PersonEntity: Name: NameFull: Kowalewski DJ – PersonEntity: Name: NameFull: Backert L – PersonEntity: Name: NameFull: Schuster H – PersonEntity: Name: NameFull: Werner JO – PersonEntity: Name: NameFull: Klein R – PersonEntity: Name: NameFull: Kohlbacher O – PersonEntity: Name: NameFull: Kanz L – PersonEntity: Name: NameFull: Salih HR – PersonEntity: Name: NameFull: Rammensee HG – PersonEntity: Name: NameFull: Stevanović S – PersonEntity: Name: NameFull: Walz JS IsPartOfRelationships: – BibEntity: Dates: – D: 14 M: 02 Text: 2018 Feb 14 Type: published Y: 2018 Identifiers: – Type: issn-print Value: 2162-4011 Numbering: – Type: volume Value: 7 – Type: issue Value: 4 Titles: – TitleFull: Oncoimmunology Type: main |
| ResultId | 1 |
